This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Inactivation of the AIDS Virus During Routine Vaccine Manufacture

Donald P. Francis, MD; Paul M. Feorino, PhD; Steven McDougal, MD; Donna Warfield; Jane Getchell, PhD; Cy Cabradilla, PhD; Myron Tong, MD; William J. Miller, MS; Loren D. Schultz, PhD; Fred J. Bailey; William J. McAleer, PhD; Edward M. Scolnick, MD; Ronald W. Ellis, PhD

JAMA. 1986;256(7):869-872.

Abstract
In the United States, one hepatitis B vaccine (Heptavax-B) has been licensed for the prevention of hepatitis B virus infections. Even though this vaccine has been shown to be highly effective and well tolerated in controlled trials and has been recommended for use in those at risk for acquiring infection by hepatitis B virus, many individuals have been reluctant to be immunized for fear of contracting acquired immunodeficiency syndrome (AIDS). In this study, we demonstrate that (1) each of the three inactivation steps used in the manufacture of Heptavax-B independently will inactivate the infectivity of high-titered preparations of the AIDS virus; (2) recipients of the hepatitis B vaccine do not develop antibodies to the AIDS virus; (3) the hepatitis B vaccine does not contain detectable levels of nucleic acids related to the AIDS virus. These observations clearly demonstrate that vaccination with the currently available hepatitis B vaccine poses no demonstrable risk for acquiring AIDS.

(JAMA 1986;256:869-872)

Author Affiliations
From the Divisions of Viral Diseases and Host Factors, Center for Infectious Diseases, Centers for Disease Control, Atlanta (Drs Francis, Feorino, McDougal, Getchell, and Cabradilla and Ms Warfield); the Liver Center, Huntington Memorial Hospital, Pasadena, Calif (Dr Tong); and the Department of Virus and Cell Biology, Merck Sharp & Dohme Research Laboratories, West Point, Pa (Drs Schultz, McAleer, Scolnick, and Ellis and Messrs Miller and Bailey).

Footnotes
Reprint requests to Virology Section, Centers for Disease Control, Bldg 7-5B 47, Atlanta, GA 30333 (Dr Feorino).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening for Hepatocellular Carcinoma in High-Risk Individuals: A Clinical Review
Regan
Arch Intern Med 1989;149:1741-1744.
ABSTRACT  

Prevention of Hepatitis B in Surgeons and Their Patients
Reese and Ockner
PERSPECT VASC SURG ENDOVASC THER 1989;2:138-147.
 

Lack of Response to Recombinant Hepatitis B Vaccine in Nonresponders to the Plasma Vaccine
Weissman et al.
JAMA 1988;260:1734-1738.
ABSTRACT  

Do Alternate Modes for Transmission of Human Immunodeficiency Virus Exist? A Review
Lifson
JAMA 1988;259:1353-1356.
ABSTRACT  

Update on Hepatitis B Prevention: Recommendations of the Immunization Practices Advisory Committee
ANN INTERN MED 1987;107:353-357.
ABSTRACT  

Leads From the MMWR
JAMA 1987;258:437-449.
 

Hepatitis B Vaccines--to Switch or Not to Switch
Hollinger
JAMA 1987;257:2634-2636.
ABSTRACT  

The Prevention of Acquired Immunodeficiency Syndrome in the United States: An Objective Strategy for Medicine, Public Health, Business, and the Community
Francis and Chin
JAMA 1987;257:1357-1366.
ABSTRACT  

The Safety of the Hepatitis B Vaccine
Meric
JAMA 1987;257:315-316.
ABSTRACT